These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9535245)

  • 1. Immunization of children with pertussis toxoid decreases spread of pertussis within the family.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Pediatr Infect Dis J; 1998 Mar; 17(3):196-9. PubMed ID: 9535245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Bryla DA; Robbins JB
    J Pediatr; 1997 Apr; 130(4):532-6. PubMed ID: 9108848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of a pertussis-toxoid vaccine.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
    N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants.
    Taranger J; Trollfors B; Lagergård T; Lind L; Sundh V; Zackrisson G; Bryla DA; Robbins JB
    Pediatr Infect Dis J; 1997 Feb; 16(2):180-4. PubMed ID: 9041597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
    Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Sundh V; Lagergård T; Lind-Brandberg L; Zackrisson G; White J; Cicirello H; Fusco J; Robbins JB
    Clin Infect Dis; 2001 Oct; 33(7):1004-10. PubMed ID: 11528572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid.
    Trollfors B; Taranger J; Lagergård T; Sundh V
    Pediatr Infect Dis J; 2005 Jan; 24(1):85-6. PubMed ID: 15665717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
    Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.
    Khodr ZG; Bukowinski AT; Gumbs GR; Conlin AMS
    Vaccine; 2017 Oct; 35(42):5603-5610. PubMed ID: 28916245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.